Next GLP-1 Billion-Dollar Market: Fireside Chat with Conexeu Sciences CEO Miles Harrison

Next GLP-1 Billion-Dollar Market: Fireside Chat with Conexeu Sciences CEO Miles Harrison

IPO Edge

Mon, August 3, 2026 at 5:55 PM GMT+3 2 min read

IPO Edge hosted a fireside chat with Conexeu Sciences Inc. (Nasdaq: CNXU) President and Chief Executive Officer Miles Harrison, moderated by IPO Edge Editor-in-Chief John Jannarone and Editor-at-Large Jarrett Banks in a video session lasting approximately 30 minutes.

Mr. Harrison discussed:

• How the company is developing tissue-regeneration technology for wound care, aesthetics, oral health, veterinary medicine and reconstruction.

• Why widespread weight-loss drug use is driving demand for treatments that restore lost facial and body volume.

• Conexeu aims to address large-volume tissue restoration, an area current fillers and injectables do not adequately serve.

• Focus on one core technology intended to support multiple medical applications, improving development efficiency.

• The company developing a bioresorbable regenerative scaffold as a potential alternative to silicone breast implants.

• Key upcoming catalysts with FDA 510(k) submission and review, additional data publications, breast program progress and expansion into dental and veterinary markets.

WATCH MORE

Beyond Mega IPOs: ICR Capital President & Chairman Don Duffy, Live from NYSE

About Conexeu Sciences Inc. (Nasdaq: CNXU)

Architecting bioregeneration. Conexeu Sciences is a preclinical-stage regenerative tissue platform company. Our patented bioregenerative extracellular matrix (ECM) platform, CXU, is built on a single structural principle: one formula, one device, designed to scale across multiple addressable markets.

Conexeu is targeting large, multi-billion-dollar end markets, including wound care, periodontal applications, and facial and body tissue restoration, including the tissue changes that can follow GLP-1 weight loss, with further expansion opportunities in 3D printing and biofabrication workflows and the veterinary market. The Company is advancing a predicate-based U.S. regulatory strategy with an anticipated 510(k) submission in early 2027 for its initial indication, subject to regulatory review.

Conexeu is led by an experienced leadership team with deep expertise in biomaterials, regenerative medicine, and medical device commercialization and development.

WATCH MORE

Delivering Measurable AI Strategies: ICR CEO Anton Nicholas, Live at Nasdaq

About Miles Harrison

Miles Harrison is a 30-year global healthcare leader developing and building category-defining brands. Current board member of Castle Biosciences (Nasdaq: CSTL), a precision diagnostics company.

8-Figure Exit, Novaestiq Corp. Co-Founder and CEO, built the "next-generation" aesthetics platform, raised $10M+ pre-Series A, and FDA approved in September 2025.

Member of Galderma's North American President & GM, scaling Aesthetics, Consumer, and Prescription businesses by 50%+ to $2.1B+across Dysport, Sculptra, Restylane, Cetaphil, Differin, Proactiv and Epiduo.

Attained the 1st FDA-approved RX-to-OTC acne switch in 30 years.

SVP and VP for Novartis across multiple verticals-Pharma, Oncology, Nutrition and Consumer.

Never Miss our Weekly Highlights HERE

Contact:

IPO Edge

www.IPO-Edge.com

Editor@IPO-Edge.com

Click HERE to follow us on LinkedIn